A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) of XZP-5610 Tablets Following Single- and Multiple-ascending Doses (SAD/MAD) and Food Effects in Healthy Subjects.

Xuanzhu Biopharmaceutical Co., Ltd.1 个研究点分布在 1 个国家目标入组 112 人开始时间: 2021年5月31日最近更新: 2021年6月4日

适应症

干预措施

试验速览

阶段: 1 期
发起方: Xuanzhu Biopharmaceutical Co., Ltd.
入组人数: 112
试验地点: 1
主要终点: AUClast

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This study will consist of 3 parts: Part A - Single Ascending Dose (SAD) phase, Part B - multiple ascending dose (MAD) phase, and Part C - Food Effect (FE) phase.

详细描述

Part A and Part B studies were designed as single-center, randomized, double-blind, placebo-controlled, dose-escalation trials to assess the safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) profiles of single and multiple oral doses of XZP-5610 tablets in healthy adult subjects, and exploring preliminary food effects (non-high-fat meals) in the Part B study. Part C is a single-center, randomized, open, 2×2 crossover design designed to assess the foodeffects on PK of a single oral dose of XZP-5610 tablets in healthy adult subjects.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Parallel
主要目的: Treatment
盲法: Double (Participant, Investigator)

入排标准

年龄范围: 18 Years 至 60 Years（Adult）
性别: All
接受健康志愿者: 是

入选标准

•Healthy adult males or females aged 18 to 60 years (inclusive).
•Body weight ≥ 50 kg for males and ≥ 45 kg for females; body mass index (BMI) in the range 19.0-28.0 kg/m2 for the non-obese group and in the range of 28.1 -35.0 kg/ 2 for the obese group (inclusive, BMI=weight/height2).
•No plans to have children within the last 6 months, no plans to donate sperm/egg, and willing to use effective contraception within 6 months after the end of dosing
•No clinically significant vital signs, physical examination, laboratory tests, or ECG or chest radiograph findings.
•Subjects understand and comply with the study procedures, voluntarily participate, and sign an Informed Consent Form.

排除标准

•History or presence of severe systemic diseases such as endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary or major neurological (including stroke and chronic epilepsy) abnormalities.
•History of clinically significant ECG abnormalities or family history of long QT syndrome (grandparents, parents and siblings)
•Any of the following was regarded as a criterion for exclusion:
•Confirmation of QTcF ≥ 450 ms by repeated measurements;
•Confirmation of QRS duration > 120 ms by repeated measurements;
•Confirmation of PR interval > 200 ms by repeated measurements;
•Findings that lead to difficulties in QTc measurement or difficult interpretation of QTc data;
•History of other risk factors for Torsades de Pointes tachycardia (e.g., heart failure, hypokalemia, family history of long QT syndrome);
•Presence of uncorrected hypokalemia or hypomagnesemia.
•Parts B and C:
•Any of the following was regarded as a criterion for exclusion:
•Family history of long QT syndrome (grandparents, parents and siblings);
•Resting QTcF ≥ 450 ms (males) or ≥ 460 ms (females) during the screening or baseline period.
•Subjects with a known or suspected history of allergy to the test drug or its adjuvant components, or a history of clinically significant severe allergy (e.g., food, drug, latex allergy), or a history of atopic allergic disease (asthma, urticaria, eczematous dermatitis)
•History of dysphagia or any gastrointestinal disorder affecting drug absorption at screening, including history of frequent nausea or vomiting of any etiology, history of irregular gastrointestinal motility such as habitual diarrhea, constipation or bowel pre-excitation syndrome, or history of major gastrointestinal surgery (e.g., gastrectomy, gastrointestinal anastomosis, bowel resection, gastric bypass, gastric division, or gastric banding)
•History of pancreatic injury or pancreatitis at screening, or significantly elevated blood amylase (> 1.5 x ULN)
•History of urinary tract obstruction or presence of urinary voiding difficulties at screening.
•History of cancer (malignancy) at the time of screening.
•Positive test results for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody or syphilis antibody
•History of significant drug abuse within 12 months prior to screening or positive urine drug screening
•Regular alcohol consumption within 3 months prior to screening, consuming more than 3 alcoholic drinks per day (one drink is approximately equal to: beer 354 mL/12 ounces, wine 118 mL/4 ounces, or distilled spirits 29.5 mL/1 ounce), or evidence of alcohol abuse and excessive consumption as evidenced by alcohol breath test at screening (subjects who consume 4 alcoholic beverages per day may be enrolled at the investigator's (enrollment is at the discretion of the investigator).
•History of smoking within 3 months prior to screening, or a positive urine nicotine test at screening, or who cannot give up smoking throughout the study period
•Excessive daily intake of coffee, tea, cola, energy drinks, or other caffeinated beverages within 3 months prior to screening, with excess defined as more than 6 servings (one servingis approximately equal to 120 mg of caffeine).
•Major surgery, or donation or loss of blood over 400 mL within 3 months prior to administration.
•Participation in other clinical trials and treatment with investigational productinvestigational product within 3 months prior to administration.
•Taken any prescription, over-the-counter, nutraceutical, herbal or proprietary Chinese medicine within 4 weeks prior to administration (or less than 5 half-lives of the drug from the start of the trial).
•Women who are pregnant or breastfeeding, or of childbearing potential who are not using effective non-hormonal contraception (intrauterine device (IUD), barrier method with spermicide, or surgical sterilization, etc.) or are unwilling to continue using these methods during the trial until 6 months after discontinuation; men of childbearing potential who are unwilling to use physical methods of contraception during the trial until 6 months after discontinuation.
•Systolic blood pressure ≥ 140 mmHg or < 90 mmHg, and/or diastolic blood pressure ≥ 90 mmHg or < 50 mmHg at screening or prior to dosing
•Heart rate < 50 or > 100 beats/min at screening or prior to dosing.
•The estimated glomerular filtration rate (eGFR) < 90 ml/min/ 1.73m2 at screening based on the Modification of Diet in Renal Disease Study (MDRD) formula (see Appendix 1 for calculation formula).
•At screening, the liver function tests of non-obese group showed any measure of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), or total bilirubin> upper limit of normal (ULN); the liver function tests of obese group showed AST, ALT, or ALP> 1.5 × ULN, or total bilirubin> ULN.
•Fasting triglycerides > 200 mg/dL (2.27 mmol/L) at screening.
•Fasting glucose > 5.6 mmol/L in the non-obese group and > 6.1 mmol/L or glycosylated hemoglobin (HbA1c) ≥ 6.5% in the obese group at screening.
•Those who could not tolerate blood sample collection.
•Subjects who are deemed by the investigator to be unsuitable for participation in the study.

研究组 & 干预措施

Part A-experimental

Experimental

Single Ascending Dose (SAD) phase

干预措施: XZP-5610 Tablet (for Part A) (Drug)

Part A-placebo

Placebo Comparator

Single Ascending Dose (SAD) phase

干预措施: Placebo to match XZP-5610 Tablet (for Part A) (Drug)

Part B-experimental

Experimental

multiple ascending dose (MAD) phase

干预措施: XZP-5610 Tablet (for Part B) (Drug)

Part B-placebo

Placebo Comparator

multiple ascending dose (MAD) phase

干预措施: Placebo to match XZP-5610 Tablet (for Part B) (Drug)

Part C1-experimental

Experimental

Food Effect (FE) phase

干预措施: XZP-5610 Tablet （for "Part C1"） (Drug)

Part C1-experimental

Experimental

Food Effect (FE) phase

干预措施: XZP-5610 Tablet for "Part C2" (Drug)

Part C2-experimental

Experimental

Food Effect (FE) phase

干预措施: XZP-5610 Tablet （for "Part C1"） (Drug)

Part C2-experimental

Experimental

Food Effect (FE) phase

干预措施: XZP-5610 Tablet for "Part C2" (Drug)